Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Oramed Pharmaceuticals (ORMP) Return on Capital Employed (2016 - 2026)

Oramed Pharmaceuticals (ORMP) has disclosed Return on Capital Employed for 15 consecutive years, with 6.96% as the latest value for Q1 2026.

  • Quarterly Return on Capital Employed rose 1031.0% to 6.96% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 6.96% through Mar 2026, up 1031.0% year-over-year, with the annual reading at 9.09% for FY2025, 1093.0% up from the prior year.
  • Return on Capital Employed hit 6.96% in Q1 2026 for Oramed Pharmaceuticals, down from 7.66% in the prior quarter.
  • Over the last five years, Return on Capital Employed for ORMP hit a ceiling of 7.66% in Q4 2025 and a floor of 35.12% in Q3 2022.
  • Median Return on Capital Employed over the past 5 years was 2.81% (2025), compared with a mean of 9.55%.
  • On a YoY basis, Return on Capital Employed climbed as much as 2807bps in 2023 and fell as far as -714bps in 2023.
  • Year by year, Return on Capital Employed stood at 27.45% in 2022, then soared by 102bps to 0.62% in 2023, then crashed by -450bps to 2.16% in 2024, then surged by 454bps to 7.66% in 2025, then dropped by -9bps to 6.96% in 2026.
  • Business Quant data shows Return on Capital Employed for ORMP at 6.96% in Q1 2026, 7.66% in Q4 2025, and 1.93% in Q3 2025.